The Bull Rankings scorecard — our quality-growth score is 79 / 100, built from three pillars each graded 0–100 against sector peers: Quality 73, Growth 100, Value 68. At today's price, our reverse-DCF read says the market is implicitly betting on about 24% a year in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
Insulet’s latest quarter cemented the view that the stock is over‑priced at $133.26. The market is demanding a 31.1 × PE and a 3 × PS for a company that just posted 29.4 % FY revenue growth and a 12.3 % profit margin. Those multiples already assume the 24 % /yr free‑cash‑flow growth the Bull Rankings model extracts from the reverse‑DCF. That implied growth is well above the 29.4 % FY top‑line expansion, but it ignores the fact that guidance was cut for the U.S. Omnipod line, a segment that historically drives the bulk of growth. In short, the price embeds a level of optimism that the newest guidance does not support.
What the business actually is
Insulet designs, builds and sells the Omnipod family of insulin‑delivery systems. The core offering, the Omnipod 5 automated insulin delivery system, runs a proprietary algorithm inside a tubeless pod that talks via Bluetooth to a third‑party continuous glucose monitor. The older Omnipod DASH pairs a Bluetooth‑enabled pod with a smartphone‑like personal diabetes manager, while the generic Omnipod Insulin Management System remains a basic, tubeless pump. All three products serve people with insulin‑dependent diabetes in the United States and abroad, with the Omnipod 5 platform being the engine of recent international expansion.
Why it can (or can't) keep compounding
The business’s Growth pillar—100 / 100 in our model—captures the 23 % constant‑currency revenue lift in the quarter and the 29.4 % FY YoY increase. That momentum is underpinned by a 12.3 % profit margin and a 26.4 % ROE, indicating the firm converts sales into earnings and shareholder return with efficiency that outpaces most med‑device peers. The moat comes from the proprietary AID algorithm and the tubeless pod design, both of which require FDA clearance and a substantial patient‑training investment. Competitors would need to rebuild that regulatory and user‑experience stack from scratch, a barrier that has kept Insulet’s market share relatively insulated despite the crowded diabetes‑device field.
The valuation question
At a PE of 31.1 and a PS of 3, the stock is trading at a premium to the sector median. The Bull Rankings reverse‑DCF suggests the current price is justified only if free‑cash‑flow can sustain 24 % annual growth for a decade. That rate exceeds the 29.4 % FY revenue growth, but the recent guidance cut for the U.S. Omnipod line signals a slowdown in the segment that historically supplied the bulk of that expansion. The market is therefore pricing in a optimistic growth path that may be unrealistic unless the international outlook, which was raised, can fully offset the U.S. shortfall. The Value pillar—68 / 100—flags that the stock is expensive relative to its cash‑flow generation, reinforcing the view that the price already leans heavily on forward‑looking optimism.
The bear case
The most compelling counterargument is the lowered U.S. guidance. The latest earnings call highlighted execution issues in onboarding Type 2 patients, and analysts noted that the stock “crashed … after lowering sales guidance for its body‑worn insulin pump, Omnipod” (Yahoo, early August). A debt‑to‑equity of 0.78 also adds a modest leverage risk if cash conversion falters. Should the international rollout stumble or the algorithm fail to win new adopters, the 24 % free‑cash‑flow growth assumption would crumble, leaving the stock with a PE of 31.1 and PS of 3 that no longer reflect the underlying earnings power.
What would change our mind
First, a beat‑and‑raise on the U.S. Omnipod outlook—say, guidance lifted to a growth rate matching the FY 29.4 %—would bring the implied free‑cash‑flow growth back in line with the model’s expectations and revive the growth narrative. Second, a margin expansion beyond the current 12.3 % profit margin, perhaps driven by scale economies in the international segment, would lift the Value pillar toward the 80 + range, making the premium multiples more palatable. Finally, a significant reduction in debt‑to‑equity—dropping below 0.5—would lower financial risk and improve the quality score, potentially shifting the balance from an over‑priced view to a fair‑value one. Until one of those catalysts materialises, the price appears to be a bet on growth that the latest guidance does not fully justify.